Skip to Content
Søk Menu

ASH2020: Sustained response to Ibrutinib + Venetoclax despite planned discontinuation of therapy in MRD negative patients Relapsed/Refractory CLL

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Tereza Faitova

Gut microbiome dysbiosis could be implicated in the pathogenesis of CLL

/ Tereza Faitova
EHA22KLL Play the Video 5:04
Matthew S. Davids

ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

/ Matthew S. Davids
ASH21KLL Play the Video 2:37
Paolo Ghia

How can we use Minimal Residual Disease in the treatment of CLL?

/ Paolo Ghia
ASH21KLL Play the Video 2:03
Talha Munir

MRD analysis in 1L Treatment of CLL in Elderly or Unfit patients

/ Talha Munir
ASH21KLL Play the Video 6:06
Matthew S. Davids

Retreatment with venetoclax + anti-CD20 monoclonal antibody for patients with relapsed/refractory CLL

/ Matthew S. Davids
ASH21KLL Play the Video 2:37
Sigrid Skånland

MRD ved behandling av KLL – en oppdatering fra ASH

/ Sigrid S. Skånland
ASH21KLL Play the Video 5:15
Florence Ajchenbaum-Cymbalista

Humoral Response to COVID-19 Vaccines in patients with CLL

/ Florence Ajchenbaum-Cymbalista
ASH21COVID-19KLL Play the Video 3:34
Arnon P. Kater

Slower cancer growth after venetoclax-rituximab treatment in patients with CLL

/ Arnon P. Kater
ASH21KLL Play the Video 2:20
Carsten Utoft Niemann,

GLOW studiet: Vedvarende behandling til de mest skrøbelige patienter med CLL

/ Carsten Utoft Niemann
ASH21KLL Play the Video 3:25
Back to top